Inactive Instrument

All News CytRx Corporation Nasdaq

Equities

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License	06-04	BU
LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License	06-04	CI
Investor Presentation: June 2024	06-04	PU
LadRx: Q1 Earnings Snapshot	05-15	AQ
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
LadRx Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C Results in XOMA Making a $1 Million Milestone Payment to LadRx	01-12	AQ
Xoma to Make $1 Million Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol	01-11	DJ
LadRx Issues 2024 Update to Shareholders	01-09	BU
LadRx: Q3 Earnings Snapshot	11-14	AQ
LadRx Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
LadRx : Modification to Rights of Security Holders - Form 8-K	11/09/23	PU
LadRx: Q2 Earnings Snapshot	14/08/23	AQ
LadRx Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Investor Presentation: July 2023	14/07/23	PU
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation	22/06/23	BU
LadRx Announces Reverse Stock Split Effective as of May 17, 2023	18/05/23	BU
Reverse Split: 1 of 100	16/05/23	FA
LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
LadRx Announces Reverse Stock Split	10/05/23	BU

No results for this search